Gimv sells Biolam to its management
Antwerp (Belgium)/ France — Biolam and Gimv today announce an important step on Biolam’s growth path. Following the rapid and successful development of the group, which combines organic and external growth, Gimv is selling its shares in Biolam to the founding team, which is supported by private investors. The founders, management and their new partners will continue to focus on quality of service and care and expansion in France.
In 2019, Gimv acquired a stake with Daniel Attias in Biolam (www.groupebiolam.fr), an emerging group of clinical testing laboratories in the city of Amiens. The original plan, developed with Daniel Attias, aimed to create a leading player in the Hauts-de-France region in terms of size, clinical performance and level of service.
From the beginning, Biolam has grown very quickly thanks to a combination of establishing laboratories in underserved locations, which is an important prerequisite for accessible quality care, and strategic acquisitions. In parallel, the Group continuously invested in staff, care organization, diagnostic equipment and IT backbone to support its ambitious medical project. These efforts have enabled Biolam to become a leading laboratory group in the Hauts-de-France and Normandy region, with a solid foundation for continued success.
The company currently operates a network of more than 30 laboratories with 4 technical platforms and has an extensive pipeline of active acquisition targets. Since Gimv’s investment in 2019, Biolam has signed 7 additional acquisitions and built a leading and high-quality diagnostics organization.
The transaction announced today will strengthen the company’s relentless focus on quality service and care, as well as expansion in its regions. The management team, together with its new partners, will continue to invest in its organization while expanding its laboratory network to create an even better diagnostics company for all stakeholders.
The transaction has no material impact on the net asset value of Gimv as of September 30, 2022. Further financial details will not be disclosed.
Gautier Lefebvre, Partner at Gimv, and Kevin Klein, Principal at Gimv., state, “We are very proud to have partnered with Biolam and Daniel Attias on the company’s growth strategy, which has always put the quality of diagnostics and level of service to physicians first, especially during the pandemic. From the beginning, we were perfectly aligned with the management team, resulting in an optimal ability to build the business and seize growth opportunities. We would like to thank the management of Biolam for their successful and excellent cooperation and wish them — together with their new partners — all the best for their further growth.”
Daniel Attias, Chairman of the Biolam Group, says, “We have exceeded the goals we originally set with the Gimv team, which is a sign of very effective collaboration. We are grateful for the successful partnership with Gimv that has enabled Biolam’s evolution into an established and leading laboratory group with a solid foundation for the next phase of growth, and we look forward to continuing to grow with our new partners.”
Translated with www.DeepL.com/Translator (free version)